Who
John Charles Thomas
EVP, General Counsel
Company insider
Files Form 4 as: EVP, General Counsel, Krystal Biotech.
In numbers
- Trades disclosed
- 8
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $1.1M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 26 May 2026
- Last trade
- 25 Jun 2026
- Last filed
- 26 Jun 2026
Companies traded
Activity over time
1 May – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 25 Jun 2026filed 26 Jun 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Code M | $179K1,000 at $179.25 | filing |
| 25 Jun 2026filed 26 Jun 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $347K1,000 at $347.27 | filing |
| 25 Jun 2026filed 26 Jun 2026 | KRYS Krystal Biotechoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,000 at $0.00 | filing |
| 25 Jun 2026filed 26 Jun 2026 | KRYS Krystal Biotechoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,000 at $0.00 | filing |
| 25 Jun 2026filed 26 Jun 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Code M | $179K1,000 at $179.25 | filing |
| 25 Jun 2026filed 26 Jun 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $347K1,000 at $347.27 | filing |
| 26 May 2026filed 27 May 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $194K642 at $302.03 | filing |
| 26 May 2026filed 27 May 2026 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $194K642 at $302.03 | filing |
News
Monte Rosa Therapeutics (NASDAQ:GLUE) versus Krystal Biotech (NASDAQ:KRYS) Head to Head SurveyKRYS · tickerreport.com · 21 Oct 2026Krystal Biotech Sees Broad Antitumor Activity With KB113 In Gorlin Syndrome; Stock UpKRYS · rttnews.com · 15 Oct 2026Krystal Biotech Reports Over 80% Lesion Regression With KB113 In Gorlin SyndromeKRYS · rttnews.com · 15 Oct 2026
0 headlines in the last 90 days name John Charles Thomas; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.